검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Vincristine Sulfate (Vincristine Sulfate) AIDS Malignancy Consortium·Lugano Classification Limited Stag… ORR 95% |
|---|---|
Overview Program | Vincristine Sulfate |
Overview Company | AIDS Malignancy Consortium |
Overview Modality | ANTIBODY |
Overview Target | Lugano Classification Limited Stage Hodg |
Overview Indication | Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting, as many cancer cells overexpress folate receptor |
MoA Biomarker | biomarkers were assessed |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility.. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydrox… |
Clinical Primary efficacy | ORR 95% |
Clinical ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT03677141 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Vincristine Sulfate (Vincristine Sulfate) AIDS Malignancy Consortium·Lugano Classification Limited Stag… ORR 95% |
|---|---|
Overview Program | Vincristine Sulfate |
Overview Company | AIDS Malignancy Consortium |
Overview Modality | ANTIBODY |
Overview Target | Lugano Classification Limited Stage Hodg |
Overview Indication | Plasmablastic Lymphoma; Ann Arbor Stage I Diffuse Large B-Cell Lymphoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeting, as many cancer cells overexpress folate receptor |
MoA Biomarker | biomarkers were assessed |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility.. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydrox… |
Clinical Primary efficacy | ORR 95% |
Clinical ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT03677141 |
Clinical Data Tier / Score | A · 70 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교